---
title: "In-Silico Testing & MDR: Smarter Evidence, Not Optional Evidence"
description: "Discover how in-silico testing supports MDR compliance. Learn how simulations can strengthen your clinical evaluation and reduce reliance on animal or human testing."
url: https://qbdgroup.com/en/blog/in-silico-testing-mdr
type: "Blog post"
language: en
published: 2025-07-23
author: "Caroline Aernouts"
category: "Regulatory Affairs"
publisher: "QbD Group"
citation: "QbD Group, \"In-Silico Testing & MDR: Smarter Evidence, Not Optional Evidence\", https://qbdgroup.com/en/blog/in-silico-testing-mdr"
---
# In-Silico Testing & MDR: Smarter Evidence, Not Optional Evidence
> Discover how in-silico testing supports MDR compliance. Learn how simulations can strengthen your clinical evaluation and reduce reliance on animal or human testing.

## Example scenarios for Class II and Class III Devices

### Class II Example

Virtual simulations for orthopedic implants can predict mechanical fatigue, wear, and stress distribution—ensuring device longevity and reliability before clinical deployment.

### Class III Example

Cardiovascular devices (e.g., heart valves or stents) can be simulated to evaluate interaction with blood flow dynamics. This helps anticipate complications such as thrombosis or embolism—critical for pre-trial safety assurance.

## How to successfully integrate in-silico testing into MDR compliance

To make in-silico testing count as valid evidence under MDR, manufacturers should:

- **Clearly document and validate** the computational models used
- **Integrate results** with traditional clinical and bench data in the CER
- **Collaborate with notified bodies** to clarify expectations and ensure alignment of computational evidence with regulatory requirements with regards to the appraisal of these in-silico trials

Regulators want traceability, transparency, and technical justification—especially for high-risk or novel devices.

## Conclusion: a strategic move toward MDR compliance

In-silico testing under MDR is not just an option—it’s a smart strategic choice. It enables design decisions, faster iterations, earlier risk detection, and stronger technical files. As regulatory expectations evolve, **embracing in silico testing puts you ahead of the compliance curve**—while also improving patient safety and reducing reliance on traditional testing methods.
---
Source: https://qbdgroup.com/en/blog/in-silico-testing-mdr — © QbD Group. Quote freely with attribution and a link back.